Skip to main content
Fig. 17 | Journal of Experimental & Clinical Cancer Research

Fig. 17

From: Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma

Fig. 17

AKT3 expression in RCC tumor tissues versus in the associated normal tissue: Boxplots of the AKT3 expression level across TCGA-RCC subtypes in renal tumor (red) versus the associated normal renal tissues (blue) were presented (A). AKT3 expression among different stages of chRCC (B), ccRCC (C) and pRCC (D) versus the associated normal tissues was box-plotted. AKT3 expression was presented in the log2 (TPM + 1) scale format. Data were presented as the mean ± SD. A t-test was used to evaluate the statistical significance of the AKT3 mRNA expression level in normal renal tissues versus tumor tissues. One-way ANOVA was used to compare AKT3 expression among normal renal tissues versus different stages of RCC tumor tissues. The figure was performed using R version 4.0.3

Back to article page